SPHK1 and malignant colon neoplasm: In conclusion, our data provide a novel perspective on the mechanisms underlying the acquired resistance to vemurafenib in BRAFV600E mutant colon cancer cells that include increased regulation of SphK-catalysed S1P production and altered ceramide metabolism, in particular up-regulation of the ceramide salvage and de novo sphingolipid synthesis pathways (Figure 9).